



January 16, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

In accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company's subsidiary Jubilant Cadista Pharmaceuticals Inc., (Jubilant Cadista)'s solid oral formulations facility at Salisbury, Maryland, USA was inspected by the United States Food and Drug Administration (USFDA). USFDA has issued five observations with no repeat observations. Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations within stipulated time.

Going forward the said facility is not expected to manufacture any products as it has closed manufacturing operations as was referenced in the previous disclosure dated April 18, 2024.

The Company has received communication from USFDA at 1.17 am (IST) on Thursday, January 16, 2025.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624